logo
  

F5 Networks Q4 Results Top Estimates; CEO To Retire At FY15-end

F5 Networks, Inc. (FFIV) reported net income for the fourth quarter of $94.0 million or $1.26 per share, compared to $76.2 million or$0.97 per share for the year-ago quarter.

Excluding items, adjusted net income for the fourth quarter was $116.7 million or $1.57 per share, compared to $99.2 million or $1.26 per share in the prior year quarter.

Revenue for the fourth quarter rose 18% to $465.3 million from $395.3 million a year ago.

Analysts polled by Thomson Reuters expected the company to earn $1.48 per share on revenue of $460.67 million for the fourth quarter.

Looking forward to the first quarter, the company forecasts revenue of $460 million to $470 million, earnings of $1.10 to $1.13 per share and adjusted earnings of $1.46 to $1.49 per share. Analysts currently expect the company to earn $1.48 per share on revenue of $464.94 million for the first quarter.

Separately, F5 Networks said that President and Chief Executive Officer John McAdam plans to retire at the end of fiscal year 2015.

Al Higginson, Chair of F5's Board of Directors, said it is the Board's current intention that following Mr. McAdam's retirement from his role as President and CEO, McAdam will remain on the Board and serve as non-executive Board Chair.

McAdam will continue to work closely with the Board as part of its process for identifying his successor to ensure a smooth transition for the Company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT